Bosh sahifa4547 • TYO
add
Kissei Pharmaceutical Co Ltd
Yopilish kursi
3 690,00 ¥
Kunlik diapazon
3 625,00 ¥ - 3 725,00 ¥
Yillik diapazon
3 000,00 ¥ - 3 910,00 ¥
Bozor kapitalizatsiyasi
180,23 mlrd JPY
Oʻrtacha hajm
63,36 ming
Narx/foyda
15,12
Dividend daromadliligi
2,35%
Asosiy maydon
TYO
Bozor yangiliklari
MarketWatch
1 kun oldin
S&P 500 is on a 12-month tear as tariffs threaten 2025 outlook for U.S.
stocks
1,12%
0,35%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (JPY) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 21,30 mlrd | 20,59% |
Joriy xarajat | 10,89 mlrd | 30,69% |
Sof foyda | 1,14 mlrd | -52,63% |
Sof foyda marjasi | 5,37 | -60,69% |
Har bir ulushga tushum | — | — |
EBITDA | 765,00 mln | -45,65% |
Amaldagi soliq stavkasi | 30,04% | — |
Balans
Jami aktivlari
Jami passivlari
| (JPY) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 49,96 mlrd | 5,10% |
Jami aktivlari | 260,34 mlrd | 12,27% |
Jami passivlari | 39,57 mlrd | 30,80% |
Umumiy kapital | 220,77 mlrd | — |
Tarqatilgan aksiyalar | 44,21 mln | — |
Narxi/balansdagi bahosi | 0,74 | — |
Aktivlardan daromad | -0,36% | — |
Kapitaldan daromad | -0,42% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (JPY) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 1,14 mlrd | -52,63% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Tashkil etilgan
9-avg, 1946
Bosh ofis
Sayt
Xodimlar soni
1 779
